· Published by Health Canada · Official notice
This is duplicated text of a letter from Triton Pharma Inc. and Teva Canada Ltd. Contact the companies for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
March 26, 2014
Dear Patient,
Subject: Association of IMURAN® (azathioprine) or PURINETHOL® (mercaptopurine) with a type of blood cancer - Hepatosplenic T-Cell Lymphoma (HSTCL)
Triton Pharma Inc. and Teva Canada Ltd., in consultation with Health Canada, would like to inform you of safety information for patients receiving IMURAN® (azathioprine) or PURINETHOL® (mercaptopurine).
IMURAN® is a drug used to treat adult rheumatoid arthritis and help prevent kidney transplant rejection. PURINETHOL® is a drug approved to treat cancer (leukemias). IMURAN® and PURINETHOL® are not approved in Canada for the treatment of Inflammatory Bowel Disease (IBD).
Hepatosplenic T-cell lymphoma (HSTCL) is a rare1, aggressive and often fatal cancer.
Cases of HSTCL (including deaths) have been reported with the use of IMURAN® and PURINETHOL® in Canada and internationally mostly in patients where it is used to treat inflammatory bowel disease (IBD). A total of 238 cases of HSTCL have been reported worldwide1, indicating this cancer is rare.
Triton Pharma Inc. and Teva Canada Ltd. have sent a letter to healthcare professionals informing them of this safety information. This letter can be obtained on the Canadian website of Triton Pharma Inc. and Teva Canada Ltd. or on the Healthy Canadians Web site. If you have questions regarding your IMURAN® or PURINETHOL® prescriptions, please contact your doctor.
The complete prescribing and adverse event information for IMURAN® can be found in the approved Product Monograph2 which is available on the Health Canada website and on the Triton Pharma Inc. website.
The complete prescribing and adverse event information for PURINETHOL® can be found in the approved Product Monograph3 which is available on the Health Canada website and on the Teva Canada Ltd. website.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Any case of HSTCL or other serious or unexpected adverse reactions in patients receiving IMURAN® or PURINETHOL® should be reported to Triton Pharma Inc. or Teva Canada Ltd., respectively, or Health Canada.
Triton Pharma Inc.
665 Millway Avenue
Concord, Ontario L4K 3T8
Telephone: 1-866-429-9707
E-mail: drug.safety.triton@paladinlabs.com
Teva Canada Ltd.
30 Novopharm Court
Toronto, Ontario M1B 2K9
Telephone: 1-800-268-4127 ext. 1255005
E-mail: phv@tevacanada.com
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Sybil Dahan
President
Triton Pharma Inc.
Bruce Valliant
Director, Medical Affairs
Teva Canada Limited